Balazs Halmos, MD, MS, Montefiore Einstein Center for Cancer Care

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Before closing out their review of resectable NSCLC treatment strategies, key opinion leaders consider nuances in utilizing perioperative therapy in the current paradigm.

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses second-line treatment for patients with metastatic squamous non–small cell lung cancer (NSCLC).

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).